125 related articles for article (PubMed ID: 38301689)
1. Multiplex analysis of intratumoural immune infiltrate and prognosis in patients with stage II-III colorectal cancer from the SCOT and QUASAR 2 trials: a retrospective analysis.
Frei AL; McGuigan A; Sinha RRAK; Jabbar F; Gneo L; Tomasevic T; Harkin A; Iveson T; Saunders MP; Oien KA; Maka N; Pezzella F; Campo L; Browne M; Glaire M; Kildal W; Danielsen HE; Hay J; Edwards J; Sansom O; Kelly C; Tomlinson I; Kerr R; Kerr D; Domingo E; ; Church DN; Koelzer VH
Lancet Oncol; 2024 Feb; 25(2):198-211. PubMed ID: 38301689
[TBL] [Abstract][Full Text] [Related]
2. 3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT.
Iveson T; Boyd KA; Kerr RS; Robles-Zurita J; Saunders MP; Briggs AH; Cassidy J; Hollander NH; Tabernero J; Haydon A; Glimelius B; Harkin A; Allan K; McQueen J; Pearson S; Waterston A; Medley L; Wilson C; Ellis R; Essapen S; Dhadda AS; Harrison M; Falk S; Raouf S; Rees C; Olesen RK; Propper D; Bridgewater J; Azzabi A; Farrugia D; Webb A; Cunningham D; Hickish T; Weaver A; Gollins S; Wasan H; Paul J
Health Technol Assess; 2019 Dec; 23(64):1-88. PubMed ID: 31852579
[TBL] [Abstract][Full Text] [Related]
3. Tumour-infiltrating CD8
Glaire MA; Domingo E; Sveen A; Bruun J; Nesbakken A; Nicholson G; Novelli M; Lawson K; Oukrif D; Kildal W; Danielsen HE; Kerr R; Kerr D; Tomlinson I; Lothe RA; Church DN
Br J Cancer; 2019 Sep; 121(6):474-482. PubMed ID: 31388185
[TBL] [Abstract][Full Text] [Related]
4. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study.
Pagès F; Mlecnik B; Marliot F; Bindea G; Ou FS; Bifulco C; Lugli A; Zlobec I; Rau TT; Berger MD; Nagtegaal ID; Vink-Börger E; Hartmann A; Geppert C; Kolwelter J; Merkel S; Grützmann R; Van den Eynde M; Jouret-Mourin A; Kartheuser A; Léonard D; Remue C; Wang JY; Bavi P; Roehrl MHA; Ohashi PS; Nguyen LT; Han S; MacGregor HL; Hafezi-Bakhtiari S; Wouters BG; Masucci GV; Andersson EK; Zavadova E; Vocka M; Spacek J; Petruzelka L; Konopasek B; Dundr P; Skalova H; Nemejcova K; Botti G; Tatangelo F; Delrio P; Ciliberto G; Maio M; Laghi L; Grizzi F; Fredriksen T; Buttard B; Angelova M; Vasaturo A; Maby P; Church SE; Angell HK; Lafontaine L; Bruni D; El Sissy C; Haicheur N; Kirilovsky A; Berger A; Lagorce C; Meyers JP; Paustian C; Feng Z; Ballesteros-Merino C; Dijkstra J; van de Water C; van Lent-van Vliet S; Knijn N; Mușină AM; Scripcariu DV; Popivanova B; Xu M; Fujita T; Hazama S; Suzuki N; Nagano H; Okuno K; Torigoe T; Sato N; Furuhata T; Takemasa I; Itoh K; Patel PS; Vora HH; Shah B; Patel JB; Rajvik KN; Pandya SJ; Shukla SN; Wang Y; Zhang G; Kawakami Y; Marincola FM; Ascierto PA; Sargent DJ; Fox BA; Galon J
Lancet; 2018 May; 391(10135):2128-2139. PubMed ID: 29754777
[TBL] [Abstract][Full Text] [Related]
5. Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer.
Salama P; Phillips M; Grieu F; Morris M; Zeps N; Joseph D; Platell C; Iacopetta B
J Clin Oncol; 2009 Jan; 27(2):186-92. PubMed ID: 19064967
[TBL] [Abstract][Full Text] [Related]
6. Mutation burden and other molecular markers of prognosis in colorectal cancer treated with curative intent: results from the QUASAR 2 clinical trial and an Australian community-based series.
Domingo E; Camps C; Kaisaki PJ; Parsons MJ; Mouradov D; Pentony MM; Makino S; Palmieri M; Ward RL; Hawkins NJ; Gibbs P; Askautrud H; Oukrif D; Wang H; Wood J; Tomlinson E; Bark Y; Kaur K; Johnstone EC; Palles C; Church DN; Novelli M; Danielsen HE; Sherlock J; Kerr D; Kerr R; Sieber O; Taylor JC; Tomlinson I
Lancet Gastroenterol Hepatol; 2018 Sep; 3(9):635-643. PubMed ID: 30042065
[TBL] [Abstract][Full Text] [Related]
7. The intratumoural subsite and relation of CD8(+) and FOXP3(+) T lymphocytes in colorectal cancer provide important prognostic clues.
Ling A; Edin S; Wikberg ML; Öberg Å; Palmqvist R
Br J Cancer; 2014 May; 110(10):2551-9. PubMed ID: 24675384
[TBL] [Abstract][Full Text] [Related]
8. [Prognostic value of tumor infiltration immune cells in pancreatic cancer].
Zhao KL; Liu J; Jiang WN; Hao JH
Zhonghua Wai Ke Za Zhi; 2018 Jun; 56(6):464-470. PubMed ID: 29886672
[No Abstract] [Full Text] [Related]
9. Combined Low Densities of FoxP3
Cavalleri T; Bianchi P; Basso G; Celesti G; Grizzi F; Bossi P; Greco L; Pitrone C; Valtorta E; Mauri G; Truini M; Dall'Olio FG; Brandi G; Sartore-Bianchi A; Ricciardiello L; Torri V; Rimassa L; Siena S; Mantovani A; Malesci A; Laghi L;
Cancer Immunol Res; 2019 May; 7(5):751-758. PubMed ID: 30804005
[TBL] [Abstract][Full Text] [Related]
10. Intratumoural-infiltrating CD4 + and FOXP3 + T cells as strong positive predictive markers for the prognosis of resectable colorectal cancer.
Kuwahara T; Hazama S; Suzuki N; Yoshida S; Tomochika S; Nakagami Y; Matsui H; Shindo Y; Kanekiyo S; Tokumitsu Y; Iida M; Tsunedomi R; Takeda S; Yoshino S; Okayama N; Suehiro Y; Yamasaki T; Fujita T; Kawakami Y; Ueno T; Nagano H
Br J Cancer; 2019 Oct; 121(8):659-665. PubMed ID: 31488881
[TBL] [Abstract][Full Text] [Related]
11. Chromatin organisation and cancer prognosis: a pan-cancer study.
Kleppe A; Albregtsen F; Vlatkovic L; Pradhan M; Nielsen B; Hveem TS; Askautrud HA; Kristensen GB; Nesbakken A; Trovik J; Wæhre H; Tomlinson I; Shepherd NA; Novelli M; Kerr DJ; Danielsen HE
Lancet Oncol; 2018 Mar; 19(3):356-369. PubMed ID: 29402700
[TBL] [Abstract][Full Text] [Related]
12. Inclusion of BLIMP-1
Ward-Hartstonge KA; McCall JL; McCulloch TR; Kamps AK; Girardin A; Cretney E; Munro FM; Kemp RA
Cancer Immunol Immunother; 2017 Apr; 66(4):515-522. PubMed ID: 28116480
[TBL] [Abstract][Full Text] [Related]
13. 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial.
Iveson TJ; Kerr RS; Saunders MP; Cassidy J; Hollander NH; Tabernero J; Haydon A; Glimelius B; Harkin A; Allan K; McQueen J; Scudder C; Boyd KA; Briggs A; Waterston A; Medley L; Wilson C; Ellis R; Essapen S; Dhadda AS; Harrison M; Falk S; Raouf S; Rees C; Olesen RK; Propper D; Bridgewater J; Azzabi A; Farrugia D; Webb A; Cunningham D; Hickish T; Weaver A; Gollins S; Wasan HS; Paul J
Lancet Oncol; 2018 Apr; 19(4):562-578. PubMed ID: 29611518
[TBL] [Abstract][Full Text] [Related]
14. Immunoscore Combining CD8, FoxP3, and CD68-Positive Cells Density and Distribution Predicts the Prognosis of Head and Neck Cancer Patients.
Furgiuele S; Descamps G; Lechien JR; Dequanter D; Journe F; Saussez S
Cells; 2022 Jun; 11(13):. PubMed ID: 35805132
[TBL] [Abstract][Full Text] [Related]
15. A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation.
Prat A; Guarneri V; Paré L; Griguolo G; Pascual T; Dieci MV; Chic N; González-Farré B; Frassoldati A; Sanfeliu E; Cejalvo JM; Muñoz M; Bisagni G; Brasó-Maristany F; Urso L; Vidal M; Brandes AA; Adamo B; Musolino A; Miglietta F; Conte B; Oliveira M; Saura C; Pernas S; Alarcón J; Llombart-Cussac A; Cortés J; Manso L; López R; Ciruelos E; Schettini F; Villagrasa P; Carey LA; Perou CM; Piacentini F; D'Amico R; Tagliafico E; Parker JS; Conte P
Lancet Oncol; 2020 Nov; 21(11):1455-1464. PubMed ID: 33152285
[TBL] [Abstract][Full Text] [Related]
16. The Prognostic Value of FoxP3+ Tumour-Infiltrating Lymphocytes in Rectal Cancer Depends on Immune Phenotypes Defined by CD8+ Cytotoxic T Cell Density.
Schnellhardt S; Hirneth J; Büttner-Herold M; Daniel C; Haderlein M; Hartmann A; Fietkau R; Distel L
Front Immunol; 2022; 13():781222. PubMed ID: 35140715
[TBL] [Abstract][Full Text] [Related]
17. Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy.
Dieci MV; Tsvetkova V; Griguolo G; Miglietta F; Tasca G; Giorgi CA; Cumerlato E; Massa D; Lo Mele M; Orvieto E; Guarneri V; Conte P
Eur J Cancer; 2020 Sep; 136():7-15. PubMed ID: 32622323
[TBL] [Abstract][Full Text] [Related]
18. A clinical decision support system optimising adjuvant chemotherapy for colorectal cancers by integrating deep learning and pathological staging markers: a development and validation study.
Kleppe A; Skrede OJ; De Raedt S; Hveem TS; Askautrud HA; Jacobsen JE; Church DN; Nesbakken A; Shepherd NA; Novelli M; Kerr R; Liestøl K; Kerr DJ; Danielsen HE
Lancet Oncol; 2022 Sep; 23(9):1221-1232. PubMed ID: 35964620
[TBL] [Abstract][Full Text] [Related]
19. High intratumoral FOXP3⁺ T regulatory cell (Tregs) density is an independent good prognosticator in nodal negative colorectal cancer.
Hanke T; Melling N; Simon R; Sauter G; Bokemeyer C; Lebok P; Terracciano LM; Izbicki JR; Marx AH
Int J Clin Exp Pathol; 2015; 8(7):8227-35. PubMed ID: 26339391
[TBL] [Abstract][Full Text] [Related]
20. The role of immune microenvironment in small-cell lung cancer: Distribution of PD-L1 expression and prognostic role of FOXP3-positive tumour infiltrating lymphocytes.
Bonanno L; Pavan A; Dieci MV; Di Liso E; Schiavon M; Comacchio G; Attili I; Pasello G; Calabrese F; Rea F; Favaretto A; Rugge M; Guarneri V; Fassan M; Conte PF
Eur J Cancer; 2018 Sep; 101():191-200. PubMed ID: 30077124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]